OpenLB
Open Library of Bioscience
Advanced Search
Molecular therapy oncolytics
Dec 20, 2019;15 38-48.

Immunotherapeutic Challenges for Pediatric Cancers.

Brian Hutzen, Mohammed Ghonime, Joel Lee, Elaine R Mardis, Ruoning Wang, Dean A Lee, Mitchell S Cairo, Ryan D Roberts, Timothy P Cripe, Kevin A Cassady
Author Information
  1. Brian Hutzen: The Research Institute at Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, The Ohio State University College of Medicine, Columbus, OH, USA.
  2. Mohammed Ghonime: The Research Institute at Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, The Ohio State University College of Medicine, Columbus, OH, USA.
  3. Joel Lee: The Ohio State University, Columbus, OH, USA.
  4. Elaine R Mardis: The Research Institute at Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, The Ohio State University College of Medicine, Columbus, OH, USA.
  5. Ruoning Wang: The Research Institute at Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, The Ohio State University College of Medicine, Columbus, OH, USA.
  6. Dean A Lee: The Research Institute at Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, The Ohio State University College of Medicine, Columbus, OH, USA.
  7. Mitchell S Cairo: Department of Pediatrics, Cancer and Blood Diseases Center, New York Medical College, Valhalla, NY, USA.
  8. Ryan D Roberts: The Research Institute at Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, The Ohio State University College of Medicine, Columbus, OH, USA.
  9. Timothy P Cripe: The Research Institute at Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, The Ohio State University College of Medicine, Columbus, OH, USA.
  10. Kevin A Cassady: The Research Institute at Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, The Ohio State University College of Medicine, Columbus, OH, USA.
PMID: 31650024 DOI: 10.1016/j.omto.2019.08.005

Abstract

Solid tumors contain a mixture of malignant cells and non-malignant infiltrating cells that often create a chronic inflammatory and immunosuppressive microenvironment that restricts immunotherapeutic approaches. Although childhood and adult cancers share some similarities related to microenvironmental changes, pediatric cancers are unique, and adult cancer practices may not be wholly applicable to our pediatric patients. This review highlights the differences in tumorigenesis, viral infection, and immunologic response between children and adults that need to be considered when trying to apply experiences from experimental therapies in adult cancer patients to pediatric cancers.

Keywords

CAR T cells brain tumor dendritic cell vaccine immunosuppression immunotherapy metabolic antagonism natural killer cells neo-antigen oncolytic virotherapy sarcoma

References

  1. Immunotherapy. 2016 Feb;8(2):145-63 [PMID: 26808918]
  2. PLoS Pathog. 2005 Sep;1(1):e7 [PMID: 16201019]
  3. Mol Cancer Res. 2016 May;14(5):482-92 [PMID: 26883073]
  4. Nat Med. 2016 Apr;22(4):433-8 [PMID: 26901407]
  5. Curr Opin Immunol. 2014 Dec;31:102-7 [PMID: 25459001]
  6. Immunol Res. 2010 Jul;47(1-3):123-33 [PMID: 20087684]
  7. Mol Ther. 2018 Nov 7;26(11):2542-2552 [PMID: 30415658]
  8. Cancer Genet Cytogenet. 1988 Jun;32(2):229-38 [PMID: 3163261]
  9. Blood. 2014 Jul 10;124(2):188-95 [PMID: 24876563]
  10. Pediatr Clin North Am. 2002 Dec;49(6):1339-68, vii-viii [PMID: 12580369]
  11. Oncotarget. 2016 Apr 26;7(17):24125-40 [PMID: 27006472]
  12. J Virol. 1998 Sep;72(9):7005-11 [PMID: 9696792]
  13. Pediatr Blood Cancer. 2010 Apr;54(4):519-25 [PMID: 19852061]
  14. Cell Metab. 2016 Jan 12;23(1):27-47 [PMID: 26771115]
  15. Trends Immunol. 2017 Aug;38(8):542-557 [PMID: 28579323]
  16. Gene Ther. 2000 May;7(10):867-74 [PMID: 10845725]
  17. Nat Med. 1998 Mar;4(3):328-32 [PMID: 9500607]
  18. N Engl J Med. 2011 Aug 25;365(8):725-33 [PMID: 21830940]
  19. Clin Cancer Res. 2017 Jul 15;23(14):3566-3574 [PMID: 28495911]
  20. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):251-9 [PMID: 14734477]
  21. J Infect Dis. 1976 Apr;133(4):456-64 [PMID: 1262711]
  22. Nat Rev Immunol. 2012 Sep;12(9):636-48 [PMID: 22918466]
  23. J Pediatr. 1986 Jan;108(1):1-12 [PMID: 3511202]
  24. Cell. 2008 Sep 5;134(5):703-7 [PMID: 18775299]
  25. Pediatr Res. 2017 Nov;82(5):872-880 [PMID: 28723886]
  26. Nat Biotechnol. 2013 Jun;31(6):471-2 [PMID: 23752412]
  27. Immunol Rev. 1996 Aug;152:175-92 [PMID: 8930673]
  28. Pediatr Blood Cancer. 2010 Dec 15;55(7):1253-63 [PMID: 20734404]
  29. Expert Opin Investig Drugs. 2000 Feb;9(2):311-27 [PMID: 11060679]
  30. J Virol. 2002 Nov;76(22):11688-703 [PMID: 12388728]
  31. Hum Vaccin Immunother. 2016 Sep;12(9):2232-9 [PMID: 27245943]
  32. Trends Immunol. 2015 Feb;36(2):71-80 [PMID: 25601541]
  33. Viruses. 2016 Feb 04;8(2):null [PMID: 26861381]
  34. PLoS One. 2012;7(1):e30264 [PMID: 22279576]
  35. Adv Exp Med Biol. 2014;816:259-313 [PMID: 24818727]
  36. N Engl J Med. 2014 Oct 16;371(16):1507-17 [PMID: 25317870]
  37. Clin Cancer Res. 2012 May 15;18(10):2780-90 [PMID: 22589486]
  38. Gene Ther. 2010 Jul;17(7):922-9 [PMID: 20508601]
  39. J Clin Invest. 2017 Apr 3;127(4):1425-1437 [PMID: 28319047]
  40. Oncogene. 2001 Sep 10;20(40):5736-46 [PMID: 11607823]
  41. Cancer Res. 2001 Dec 1;61(23):8513-9 [PMID: 11731436]
  42. J Clin Invest. 1993 Jun;91(6):2829-36 [PMID: 8514891]
  43. Int J Cancer. 1999 Oct 8;83(2):215-22 [PMID: 10471530]
  44. J Vis Exp. 2011 Feb 02;(48):null [PMID: 21339714]
  45. Oncogene. 2010 Sep 30;29(39):5346-58 [PMID: 20661219]
  46. Front Immunol. 2015 Apr 29;6:202 [PMID: 25972872]
  47. Cancer Res. 2007 Sep 1;67(17):8301-6 [PMID: 17804745]
  48. Cancer Cell. 2012 Mar 20;21(3):297-308 [PMID: 22439925]
  49. Hum Gene Ther. 1999 Sep 1;10(13):2237-43 [PMID: 10498254]
  50. Cancers (Basel). 2016 Nov 24;8(12): [PMID: 27886124]
  51. EMBO J. 1996 Sep 2;15(17):4759-66 [PMID: 8887567]
  52. Skelet Muscle. 2012 Dec 03;2(1):25 [PMID: 23206814]
  53. Nat Immunol. 2016 Aug 19;17(9):1025-36 [PMID: 27540992]
  54. Gene Ther. 2015 Apr;22(4):356 [PMID: 25832732]
  55. Int J Cancer. 2014 Sep 15;135(6):1381-9 [PMID: 24347514]
  56. Oncotarget. 2016 Apr 5;7(14):17616-30 [PMID: 26848860]
  57. Cancer J. 2014 Mar-Apr;20(2):134-40 [PMID: 24667959]
  58. J Pediatr. 2014 Mar;164(3):529-35.e1-4 [PMID: 24359940]
  59. Hum Gene Ther Clin Dev. 2017 Mar;28(1):7-16 [PMID: 28319448]
  60. N Engl J Med. 2015 Dec 10;373(24):2336-2346 [PMID: 26580448]
  61. Immunol Rev. 2013 Sep;255(1):197-209 [PMID: 23947356]
  62. Cancer Gene Ther. 2002 Dec;9(12):967-78 [PMID: 12522436]
  63. J Transl Med. 2010 Jan 29;8:10 [PMID: 20113473]
  64. Clin Cancer Res. 2009 Sep 1;15(17):5323-37 [PMID: 19723653]
  65. Clin Exp Metastasis. 2010 Mar;27(3):133-40 [PMID: 20180146]
  66. J Leukoc Biol. 2009 Nov;86(5):1065-73 [PMID: 19741157]
  67. J Med Virol. 2014 Jun;86(6):1048-55 [PMID: 24615722]
  68. Clin Cancer Res. 2014 Mar 1;20(5):1190-203 [PMID: 24277455]
  69. Autophagy. 2009 May;5(4):576-7 [PMID: 19333005]
  70. Mol Cell Biol. 1993 Dec;13(12):7393-8 [PMID: 8246959]
  71. Cold Spring Harb Perspect Med. 2013 Aug 01;3(8):null [PMID: 23906881]
  72. Clin Cancer Res. 2014 Sep 1;20(17):4442-8 [PMID: 24958807]
  73. Cancer Res. 2010 Oct 1;70(19):7465-75 [PMID: 20841473]
  74. Cancer Res. 2007 Oct 1;67(19):9371-9 [PMID: 17909046]
  75. PLoS One. 2012;7(1):e29653 [PMID: 22242177]
  76. J Pediatr. 2005 Apr;146(4):523-7 [PMID: 15812457]
  77. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1411-5 [PMID: 7877992]
  78. Science. 2002 Mar 15;295(5562):2097-100 [PMID: 11896281]
  79. Blood. 1998 Dec 1;92(11):4248-55 [PMID: 9834230]
  80. Front Immunol. 2014 Jul 28;5:358 [PMID: 25120544]
  81. Semin Pediatr Surg. 2010 Aug;19(3):225-33 [PMID: 20610196]
  82. N Engl J Med. 2001 Mar 15;344(11):801-7 [PMID: 11248155]
  83. J Cancer. 2018 Apr 19;9(10):1773-1781 [PMID: 29805703]
  84. Mol Ther Oncolytics. 2014 Dec 10;1:14004 [PMID: 27119094]
  85. Childs Nerv Syst. 2016 Mar;32(3):553-7 [PMID: 26293676]
  86. J Immunol. 1999 Aug 15;163(4):1906-13 [PMID: 10438925]
  87. Mol Ther Oncolytics. 2017 Sep 08;7:17-26 [PMID: 29034312]
  88. Semin Perinatol. 2018 Apr;42(3):191-197 [PMID: 29526382]
  89. Mol Ther Oncolytics. 2017 Mar 01;5:1-10 [PMID: 28345027]
  90. Sci Rep. 2016 Jul 26;6:30093 [PMID: 27456063]
  91. Sci Rep. 2017 May 24;7(1):2396 [PMID: 28539588]
  92. Methods Mol Biol. 2016;1441:175-93 [PMID: 27177666]
  93. Oncotarget. 2016 Dec 6;7(49):80521-80542 [PMID: 27602954]
  94. Gene Ther. 2008 Dec;15(24):1579-92 [PMID: 18701918]
  95. Nat Rev Cancer. 2013 Dec;13(12):842-57 [PMID: 24226193]
  96. Bull NYU Hosp Jt Dis. 2006;64(1-2):45-50 [PMID: 17121489]
  97. J Virol. 2012 Jan;86(1):610-4 [PMID: 22072777]
  98. Expert Opin Ther Targets. 2019 Feb;23(2):127-142 [PMID: 30556751]
  99. Annu Rev Immunol. 2015;33:787-821 [PMID: 25706097]
  100. Nat Rev Cancer. 2011 Feb;11(2):85-95 [PMID: 21258394]
  101. Clin Dev Immunol. 2012;2012:948098 [PMID: 22778768]
  102. Gene Ther. 1998 Jan;5(1):121-30 [PMID: 9536273]
  103. Vaccine. 2004 Sep 3;22(25-26):3404-10 [PMID: 15308365]
  104. J Virol. 2005 Jul;79(14):8707-15 [PMID: 15994764]
  105. J Exp Med. 1999 Dec 6;190(11):1669-78 [PMID: 10587357]
  106. Immunity. 2017 Nov 21;47(5):820-833 [PMID: 29166586]
  107. J Clin Oncol. 2002 Jun 1;20(11):2672-9 [PMID: 12039929]
  108. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2480-9 [PMID: 23610399]
  109. J Immunol. 2012 Jul 15;189(2):946-55 [PMID: 22689883]
  110. Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13 [PMID: 10681459]
  111. Chest. 2010 Apr;137(4):759-68 [PMID: 20061398]
  112. Haematologica. 2008 Dec;93(12):1852-8 [PMID: 18945751]
  113. Semin Perinatol. 1990 Aug;14(4 Suppl 1):2-9 [PMID: 2237467]
  114. Viral Immunol. 2001;14(3):227-50 [PMID: 11572634]
  115. Cancer Immunol Immunother. 2015 Oct;64(10):1251-60 [PMID: 26105625]
  116. Prostate. 2004 Jun 15;60(1):53-60 [PMID: 15129429]
  117. Hum Gene Ther. 2000 Aug 10;11(12):1683-93 [PMID: 10954902]
  118. Cancer. 2017 Oct 1;123(19):3807-3815 [PMID: 28608950]
  119. Clin Cancer Res. 2018 Dec 15;24(24):6185-6194 [PMID: 30097433]
  120. J Leukoc Biol. 2016 Jul;100(1):203-12 [PMID: 26823488]
  121. Mol Ther Nucleic Acids. 2017 Mar 17;6:315-326 [PMID: 28325298]
  122. Pediatr Blood Cancer. 2015 May;62(5):743-50 [PMID: 25307519]
  123. Blood. 2018 Jun 7;131(23):2515-2527 [PMID: 29463563]
  124. Mol Cell. 2015 Nov 19;60(4):514-23 [PMID: 26590711]
  125. Trends Immunol. 2016 Mar;37(3):208-220 [PMID: 26858199]
  126. Purinergic Signal. 2013 Jun;9(2):145-65 [PMID: 23271562]
  127. Oncolytic Virother. 2018 Jul 31;7:65-77 [PMID: 30105219]
  128. Cancer. 2007 Jul 15;110(2):326-33 [PMID: 17559122]
  129. J Virol. 1998 Nov;72(11):8620-6 [PMID: 9765401]
  130. Cell. 2017 Nov 16;171(5):1042-1056.e10 [PMID: 29056344]
  131. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 [PMID: 22437870]
  132. Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):740-745 [PMID: 28069963]
  133. N Engl J Med. 2010 Jul 29;363(5):411-22 [PMID: 20818862]
  134. J Infect Dis. 1972 Mar;125(3):257-62 [PMID: 4552644]
  135. Int J Hematol. 2014 Feb;99(2):132-40 [PMID: 24338745]
  136. F1000Res. 2016 Aug 25;5:null [PMID: 27635231]
  137. Expert Opin Biol Ther. 2004 Oct;4(10):1609-20 [PMID: 15461572]
  138. Pediatr Blood Cancer. 2015 May;62(5):751-8 [PMID: 25728527]
  139. Sci Transl Med. 2013 Aug 28;5(200):200ra116 [PMID: 23986400]
  140. Cell. 2017 Feb 9;168(4):600-612 [PMID: 28187283]
  141. Oncogene. 2005 Sep 22;24(42):6367-75 [PMID: 16007187]
  142. Nat Rev Cancer. 2014 Apr;14(4):277-89 [PMID: 24599217]
  143. J Cancer Res Clin Oncol. 2019 Jul;145(7):1917-1918 [PMID: 30539279]
  144. Semin Cancer Biol. 2017 Dec;47:185-195 [PMID: 28782608]
  145. Neuro Oncol. 2004 Jul;6(3):236-46 [PMID: 15279716]
  146. Pediatrics. 1991 Jun;87(6):890-6 [PMID: 2034495]
  147. Autoimmunity. 2006 Feb;39(1):9-19 [PMID: 16455578]
  148. N Engl J Med. 2013 Apr 18;368(16):1509-1518 [PMID: 23527958]
  149. Transl Oncol. 2018 Feb;11(1):86-93 [PMID: 29216507]
  150. Cancer Res. 1994 Jun 1;54(11):2869-72 [PMID: 8187070]
  151. Int J Tuberc Lung Dis. 2004 May;8(5):658-74 [PMID: 15137550]
  152. Neuro Oncol. 2005 Jul;7(3):213-24 [PMID: 16053696]
  153. Curr Opin Immunol. 2010 Apr;22(2):231-7 [PMID: 20144856]
  154. Thymus. 1986;8(4):225-34 [PMID: 3492066]
  155. Gene Ther. 2014 Nov;21(11):984-90 [PMID: 25119379]
  156. Oncolytic Virother. 2016 Aug 11;5:73-80 [PMID: 27579298]
  157. Leukemia. 2007 Oct;21(10):2145-52 [PMID: 17673900]
  158. Mol Ther. 2015 Mar;23(3):602-8 [PMID: 25531693]
  159. Gene Ther. 2007 Jul;14(13):1045-54 [PMID: 17429445]
  160. Blood. 2016 May 19;127(20):2406-10 [PMID: 26907630]
  161. Gene Ther. 2016 Feb;23(2):135-43 [PMID: 26583803]
  162. Cancer Res. 1993 Dec 15;53(24):5859-63 [PMID: 7503813]
  163. Curr Opin Immunol. 2010 Apr;22(2):223-30 [PMID: 20207527]
  164. Cancer Immunol Res. 2018 Dec;6(12):1499-1510 [PMID: 30352799]
  165. Trends Mol Med. 2013 Jun;19(6):355-67 [PMID: 23601906]

Grants

  1. R21 CA227926/NCI NIH HHS
  2. U01 CA232488/NCI NIH HHS
  3. R01 AI114581/NIAID NIH HHS
  4. U54 CA232561/NCI NIH HHS
  5. R01 CA222903/NCI NIH HHS
Journal Article Review
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.0cellsadultcancerspediatriccancerpatientsSolidtumorscontainmixturemalignantnon-malignantinfiltratingoftencreatechronicinflammatoryimmunosuppressivemicroenvironmentrestrictsimmunotherapeuticapproachesAlthoughchildhoodsharesimilaritiesrelatedmicroenvironmentalchangesuniquepracticesmaywhollyapplicablereviewhighlightsdifferencestumorigenesisviralinfectionimmunologicresponsechildrenadultsneedconsideredtryingapplyexperiencesexperimentaltherapiesImmunotherapeuticChallengesPediatricCancersCART cellsbraintumordendriticcellvaccineimmunosuppressionimmunotherapymetabolicantagonismnaturalkillerneo-antigenoncolyticvirotherapysarcoma

Similar Articles

Cited By